Journal
ONCOLOGY REPORTS
Volume 46, Issue 2, Pages -Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/or.2021.8123
Keywords
TRIP13; lung cancer; proliferation; apoptosis; EMT
Categories
Funding
- Health Bureau of Nantong City [WKZL2018054]
- Nantong Science and Technology Bureau [MSZ18008]
Ask authors/readers for more resources
TRIP13 upregulation in NSCLC tissues is associated with tumor metastasis and may serve as a potential biomarker for the early diagnosis and treatment of NSCLC, by promoting malignant progression of lung cancer.
Lung cancer is the most common malignant tumor type and it is associated with poor prognosis. The identification of potential biomarkers is of great significance for the early diagnosis and treatment of lung cancer. Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. The present study aimed to investigate the mechanism via which thyroid hormone receptor-interacting protein 13 (TRIP13) participates in the malignant progression of NSCLC. Immunohistochemistry, reverse transcription-quantitative PCR and western blotting were used to assess the expression level of TRIP13. According to The Cancer Genome Atlas database, TRIP13 was upregulated in NSCLC tissues compared with adjacent normal tissues. Moreover, TRIP13 knockdown increased apoptosis, induced cell cycle arrest in the S phase and inhibited the proliferation, invasion and migration of H1299 cells in vitro. Furthermore, TRIP13 upregulation was closely associated with tumor metastasis via epithelial-mesenchymal transformation. In conclusion, TRIP13 could promote the malignant progression of lung cancer, and TRIP13 may be a potential biomarker for the early diagnosis and treatment of NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available